Showing 751-760 of 790 results for "".
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- RoundTable Healthcare Partners Completes Sale of Revision Skincare and Goodier Cosmetics to Gryphon Investorshttps://practicaldermatology.com/news/roundtable-healthcare-partners-completes-sale-of-revision-skincare-and-goodier-cosmetics-to-gryphon-investors/2461000/RoundTable Healthcare Partners completed the previously announced sale of Revision Skincare and Goodier Cosmetics to Gryphon Investors. Terms of the transaction were not disclosed. Revision Skincare’s portfolio includes Nectifirm, Intellishade, D·E·J
- Derms Give Back: Caring for Veteranshttps://practicaldermatology.com/news/derms-give-back-caring-for-veterans/2460989/Caring for veterans inspires dermatologists like Joshua E. Lane, MD every single day. Dr. Lane practices in Columbus, GA, near Fort Benning, a large military base, and many of his patients are veterans. He was so moved by their service and selflessness that he joined the
- FDA Oks Endo's Anti-Cellulite Injectablehttps://practicaldermatology.com/news/fda-oks-endos-anti-cellulite-injectable/2460454/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and e
- ASLMS Names New Boardhttps://practicaldermatology.com/news/aslms-names-new-board/2460406/The American Society for Laser Medicine and Surgery (ASLMS) announced its new board during the Board of Directors meeting on April 30, 2020. Thomas E. Rohrer, MD is the new President of ASLMS is the world's largest professional organization dedicated to promoting research, education, and high
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours